Novavax Inc. (NASDAQ: NVAX) is preparing to get authorization for its coronavirus vaccine. The firm is currently near the finish line and will soon join the Pfizer/BioNTech, and Moderna in launching the vaccine to stop the spread of the novel virus. Not long ago, Novavax has disclosed that it has experienced positive results in the Phase III study, and the authorities in the countries such as the US, UK, Canada, and Europe are assessing the safety data of vaccine candidate.
US FDA has awarded the Emergency Use Authorization to the vaccine candidate, but it seems like the FDA will take some time to grant the license to the vaccine candidate of the firm. Novavax Inc has disclosed the data from its Phase III study in the UK. Currently, the firm is carrying out the Phase IIII study in Mexico, and the US, and it has commenced the study in December and intends to include 30, 000 more participants throughout more than 100 sites.
It is not wrong to say that FDA will grant the EUA to the firm’s candidate after assessing the results of these studies. The firm’s candidate data in the US is more beneficial for the regulators. And it would be worth waiting for the positive result of the study in the US and it won’t affect the vaccination campaign in the US.
The US is already using Pfizer and Moderna Inc. to vaccine the people. President Joe Biden has also ordered the vaccine doses from these two companies so there is no need to rush and to grant the other company’s vaccine a license. If we consider the UK trial of the firm, it has reported the data four months after the trial and if we look at the US trial and the firm will follow the same timeline then the firm will report the data in late April.
If the FDA authorizes Novavax's vaccine now or within the next two months, it will not make an enormous difference for investors. Earlier, the Biden government completed new orders for the Pfizer and Moderna vaccines. These commands give the country sufficient shots to immunize 300 million Americans. If we look at the U.S. population it is nearly 330 million and that contains children or others who aren't qualified for the vaccine. So, currently, there is no need for a new vaccine candidate.
But if Novavax will get the authorization for its candidate it will benefit the firm in the future because once the doses vaccine campaign will ends the government might order more shots. That’s when Novavax will get a chance if its data is aligned with its competitors.